Executive Committee

Mr. Cozadd co-founded Jazz Pharmaceuticals in 2003 and has served as the Company’s Chairperson since founding and chief executive officer since April 2009. From 1991 until 2001, he held various positions with ALZA Corporation, a pharmaceutical company acquired by Johnson & Johnson, including executive vice president and chief operating officer, with responsibility for research and development, manufacturing and sales and marketing. Previously at ALZA Corporation he held the roles of chief financial officer and vice president of corporate planning and analysis. Mr. Cozadd is a member of the board of Biotechnology Innovation Organization (BIO), a biotechnology trade association, where he serves on the Health Section Governing Board. Mr. Cozadd also serves as Chair of ACELYRIN, INC., a publicly-held biopharma company, and on the boards of two non-profit organizations, The Nueva School and SFJAZZ. He received a B.S. from Yale University with a double major in molecular biophysics & biochemistry and economics and an M.B.A. from the Stanford Graduate School of Business.

Prior to joining Jazz in 2020, Ms. Galá served as the chief financial officer of GRAIL Inc., a healthcare company focused on early cancer detection. From 2014 to 2019, she served as senior vice president and chief financial officer of Theravance Biopharma, Inc., a biopharmaceutical company, following its spin-out from Innoviva, Inc. Ms. Galá joined Innoviva in 2006 and held various roles in the finance organization before leading the company’s spin-out transaction. Prior to that, Ms. Galá served in various roles in global treasury, pharmaceutical sales and corporate strategy/business development at Eli Lilly and Company from 2001 to 2006. Before joining Eli Lilly, Ms. Galá spent seven years in the energy industry in positions focused on corporate finance, project finance, and mergers and acquisitions. Ms. Galá has served on the board of multiple biotech companies, including Gossamer Bio, Gyroscope Therapeutics (acquired by Novartis) and Corcept Therapeutics. Ms. Galá holds a B.S. in Mathematics from Vanderbilt University and an M.B.A. from Columbia Business School.

From April 2018 until May 2019, Dr. Iannone served as head of research and development and chief medical officer of Immunomedics, Inc., a biopharmaceutical company. Prior to that, from July 2014 to April 2018, Dr. Iannone served in the roles of senior vice president and head of immuno-oncology, global medicines development and the global products vice president at AstraZeneca plc, a global science-led biopharmaceutical company. From 2004 to 2014, Dr. Iannone served in management roles at Merck Co., Inc., a global biopharmaceutical company, culminating in his role as executive director and section head of oncology clinical development. From 2001 to 2004, he served as assistant professor of pediatrics and from 2004 to 2012 as adjunct assistant professor of pediatrics at the University of Pennsylvania School of Medicine. Dr. Iannone served on the board of directors of Jounce Therapeutics, Inc., a clinical-stage immune-oncology company, from January 2020 – May 2023. In May 2021, Dr. Iannone was appointed to the Board of Directors for iTeos Therapeutics, a clinical-stage immune-oncology. In June 2023, he was appointed as a Non-Executive Director to Autolus Therapeutics’ Board of Directors, a clinical-stage biopharmaceutical company. Dr. Iannone has also served on the Cancer Steering Committee of the Biomarkers Consortium/Foundation for the National Institutes of Health since 2011 and is currently on the executive committee of the Biomarkers Consortium. Dr. Iannone received a B.S. from The Catholic University of America with Summa Cum Laude honors, an M.D. from Yale University with Alpha Omega Alpha distinction, and an M.S.C.E. from University of Pennsylvania. He completed his residency and chief residency in pediatrics and a fellowship in pediatric hematology-oncology at Johns Hopkins University.

Prior to joining Jazz, Ms. Henderson held various roles of increasing responsibility at Merck KGaA including executive vice president of Global Manufacturing & Supply Chain, senior vice president APAC Region & Healthcare Sustainability lead and managing director and general manager, UK & Republic of Ireland. Prior to her tenure at Merck KGaA, Ms. Henderson held manufacturing leadership roles at Amgen and Pfizer.

Ms. Henderson received a Bachelor of Science degree in Analytical Chemistry from Dublin City University, Ireland.

From January 2018 to February 2024, Mr. Johnson served as group vice president and treasurer of Eli Lilly and Company. Joining Eli Lilly and Company in 1995, Mr. Johnson served in a variety of roles, increasing in responsibility, culminating in his role as group vice president and treasurer. Prior to his career at Lilly, Mr. Johnson served as a management consultant for McKinsey & Co. and worked with investment banks in Milan, Italy and Chicago, Illinois. Mr. Johnson received a B.S from the University of Illinois and a Master of Management from the Kellogg School of Management at Northwestern University.

Prior to joining Jazz, from 2010 until 2018, she served as vice president of human resources at Campbell Soup Company, a global food company. While there, Ms. Manna held a variety of senior leadership positions in human resources across talent management, organizational development, workforce planning, and culture development to shape the human capital strategies for the business. She also led the transformation of the HR operating model to better serve the business. From 1996 to 2010, Ms. Manna held various leadership roles at Bristol-Myers Squibb, a global biopharmaceutical company, across a wide spectrum of the human resource function, including HR business partnership, talent management, operations and compensation. She started her career at Andersen Consulting (Accenture). Ms. Manna currently serves on the Employer Advisory Board for the University of Pennsylvania, and previously served on the board of directors for Seven Oaks Acquisition Corp, a special purpose acquisition company. She received a B.S. from Binghamton University and an M.B.A. from the State University of New York at Buffalo.

John Miller was appointed senior vice president of global product strategy and program management as of September 2019. From February 2015 to September 2019, he served as Jazz’s vice president of global product strategy, and from August 2012 to February 2015, he served in various management roles within the oncology therapeutic area. Prior to that, from February 2012 to August 2012, Mr. Miller was director of US and global marketing, metabolic diseases at Alexion Pharmaceuticals, and from February 2011 to February 2012, he was director of strategic marketing at Enobia Pharma. Prior to February 2011, Mr. Miller served in various product commercialization roles at Jazz Pharmaceuticals, Inc., and Genzyme Corporation. Mr. Miller received a B.S. in biochemistry from the University of Mississippi and an M.B.A. from Boston University Graduate School of Management.

From September 2018 to July 2019, Ms. Patil served as senior vice president, general counsel and corporate secretary of Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company. Prior to that, from May 2008 to October 2016, Ms. Patil served in various management positions at Novo Nordisk Inc., culminating in her role as vice president for legal affairs and associate general counsel. Prior to 2008, she worked for several other global biopharmaceutical companies including Pfizer, GPC Biotech and Sanofi. Ms. Patil received a B.A. from Georgetown University and a J.D. and Master of Health Services Administration from the University of Michigan.

From March 2010 to December 2019 prior to joining Jazz, Ms. Pearce held various global senior management positions with Celgene Corporation, most recently as vice president and general manager of international markets. Prior to that, from August 2002 to March 2010, she served in management positions at AstraZeneca plc, culminating in her role as director of specialist care. Prior to August 2002, she worked for DuPont Pharmaceuticals. Ms. Pearce received a B.Sc. from Birmingham University, U.K. and an M.B.A. from Cranfield University, UK.